Clinical trials: Skin Infections, Bacterial
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Infection, Skin Diseases, Bacterial
Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord
The purpose of this study is to determinate whether in newborns just cleaning the umbilical stump when changing diapers (with water and soap if necessary)is effective in preventing local cord infections and not delaying cord…
- Conditions
- Infection, Skin Diseases, Bacterial, Granuloma
- Trial name
- NCT01369251
- Testing
- Hygiene, Usual alcohol care
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- ASST Fatebenefratelli Sacco
Venous Leg Ulcer, Bacterial Infections
Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers
This study will determine the effectiveness of CUTIMED® hydrophobic dressings against AQUACEL® silver dressings in bacterial colonization of vascular ulcers.
- Conditions
- Venous Leg Ulcer, Bacterial Infections, Chronic Ulcer of Skin of Lower Limb Nos
- Trial name
- CUCO-UV (NCT03667937)
- Testing
- CUTIMED, AQUACEL silver
- Where
- Spain
- Volunteers
- 204 people
- Sponsor
- University of Malaga
Bacterial Infections, Gram-Positive Bacterial Infections
What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?
Staphylococcus aureus is the most common bacteria responsible for skin, bone, and muscle infections. Recent studies from the United States have suggested that a type of this bacterium called methicillin resistant S.
- Conditions
- Bacterial Infections, Gram-Positive Bacterial Infections, Staphylococcal Infections
- Trial name
- CA-MRSA (NCT00736554)
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hidradenitis Suppurativa
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
- Trial name
- NCT04493502
- Testing
- LY3041658
- Where
- 20 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Onychomycosis
Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications
In a sham controlled double-blind trial we aim to establish the efficacy and safety of local application of laser therapy in patients with diabetes with onychomycosis and risk factors for diabetes related foot complications.
- Trial name
- LASER-1 (NCT01996995)
- Testing
- Nd:YAG laser pulse therapy
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Medical Research Foundation, The Netherlands
Hidradenitis Suppurativa
Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa
Determination of the short and long term efficacy of NdYag laser for treatment of Hidradenitis suppurativa, which is an inflamed, deeper follicular disorders.
- Trial name
- NCT00494351
- Testing
- Long-pulsed Nd:YAG laser 1064 nm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Henry Ford Health System
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the…
- Trial name
- NCT03233438
- Testing
- Dalbavancin, Usual Care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Allergan
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent…
- Trial name
- STOP-HS LTE (NCT06212999)
- Testing
- Povorcitinib
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 617 people
- Sponsor
- Incyte Corporation
Disability or Chronic Disease Leading to Disablement, Pressure Ulcer
Treatment of Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and Anti-bacterial Agents
People with neuromotor disability (i.e. following an inborn or acquired spinal cord, cerebral or peripheral neurological lesion) are at high risk of osteomyelitis-associated pressure ulcers.
- Conditions
- Disability or Chronic Disease Leading to Disablement, Pressure Ulcer, Osteomyelitis
- Trial name
- NCT05713149
- Testing
- Surgical flap and anti-bacterial agents
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Institut de Sante Parasport Connecte Synergies
Skin and Subcutaneous Tissue Bacterial Infections
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA 200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults.
- Trial name
- ABSSSI (NCT01170221)
- Testing
- TR-701 FA, Linezolid
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 667 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Arthritis, Rheumatoid, Spondyloarthritis
Pain Catastrophizing and Routine Assessment of Patient Index Data 3(RAPID3) in Ten Categories of Rheumatology Outpatients
Fulfilling by all patients consequently seen by 6 rheumatologists in a same outpatient rheumatology clinic (in at least one month period) of a set of 6 questionnaires, including RAPID3 and pain catastrophizing scales.
- Conditions
- Arthritis, Rheumatoid, Spondyloarthritis, Inflammatory Rheumatisms, Systemic Disorders
- Trial name
- NCT03306784
- Testing
- questionnaires
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Nantes University Hospital
Hidradenitis Suppurativa
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa.
- Trial name
- BRIGHTEN (NCT07170917)
- Testing
- Brivekimig
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 208 people
- Sponsor
- Sanofi
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Onychomycosis
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose…
- Trial name
- NCT00602342
- Testing
- Terbinafine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Onychomycosis
A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail
Approximately 40 qualified subjects with mild-to-moderate great toenail fungus infection will be treated for 48 weeks with lacquer application to at least one affected great toenail.
- Trial name
- NCT00385502
- Testing
- EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abeona Therapeutics, Inc
Hidradenitis Suppurativa
Mindfulness in Hidradenitis Suppurativa
The study will investigate the impact of an 8-week-long Mindfulness-Based Stress Reduction course on quality of life and disease severity in patients with hidradenitis suppurativa (HS).
- Trial name
- NCT06123429
- Testing
- Mindfulness Based Stress reduction
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Onychomycosis
The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis
This will be an interventional safety and efficacy study of CELENT07 when used as a topical treatment of onychomycosis in the toenails (tinea unguium) of adults 18 years and older.
- Trial name
- NCT02644551
- Testing
- CELEXT07, Penlac, vehicle solution
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- 9305-9954 Quebec Inc
Hidradenitis Suppurativa
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions.
- Trial name
- NCT03929835
- Testing
- Cannabis oil
- Where
- Israel
- Sponsor
- TO Pharmaceuticals